Canopus Biopharma Incorporated Stock Short Ratio
| CBIA Stock | USD 0.0001 0.00 0.00% |
Canopus BioPharma Incorporated fundamentals help investors to digest information that contributes to Canopus BioPharma's financial success or failures. It also enables traders to predict the movement of Canopus Pink Sheet. The fundamental analysis module provides a way to measure Canopus BioPharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Canopus BioPharma pink sheet.
Canopus |
Canopus BioPharma Incorporated Company Short Ratio Analysis
Canopus BioPharma's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Canopus BioPharma Incorporated has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Financial Services sector and about the same as Shell Companies (which currently averages 0.0) industry. The short ratio for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Odds Of Bankruptcy Now
Odds Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years |
| All Next | Launch Module |
Canopus Fundamentals
| Shares Outstanding | 9.3 M | |||
| Net Income | 1.68 M | |||
| Cash Flow From Operations | 1.98 M | |||
| Beta | -2.23 | |||
| Market Capitalization | 364.56 K | |||
| Total Asset | 1.56 M | |||
| Retained Earnings | (10.29 M) | |||
| Current Asset | 92 K | |||
| Current Liabilities | 2.36 M | |||
| Z Score | -8.4 | |||
| Net Asset | 1.56 M |
About Canopus BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Canopus BioPharma Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Canopus BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Canopus BioPharma Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Canopus Pink Sheet
Canopus BioPharma financial ratios help investors to determine whether Canopus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Canopus with respect to the benefits of owning Canopus BioPharma security.